Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.
Women should have access to the medicines they need to live their best and fullest lives. Medicines360 is helping in a unique way.OUR MISSION
FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years
Approval Offers Women Additional Flexibility for Pregnancy Prevention DUBLIN and SAN FRANCISCO – Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use […]
how we work
We’re reinventing the pharma business model: we identify areas in women’s health where patients face limited choices, develop medicines that expand women’s options and make them available in ways that close gaps in access.
We believe women should have access to medicines, regardless of their diverse needs. As we choose products for development and study them in robust clinical trials, we tackle areas where many women struggle with limited medicine choices.PRODUCTS & PIPELINE